Last reviewed · How we verify
NCT04784026
Dual Task Gait Performance in Pediatric Oncology Patients
trial testing Gait assessment (single) in Pediatric Cancer in 40 participants. Status unknown.
20 March 2023
Quick facts
| Lead sponsor | Afyonkarahisar Health Sciences University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 March 2021 |
| Primary completion | 20 March 2023 |
| Estimated completion | 20 March 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Gait assessment (single)
- Dual task gait assessment (motor+motor)
- Dual tak gait assessment (motor+cognitive)
Conditions studied
- Pediatric Cancer — all drugs for Pediatric Cancer →
Sponsor
Afyonkarahisar Health Sciences University
Who can join
Adults 6 to 18, any sex, with Pediatric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cancer incidence, which is recognized as the leading cause of death in children worldwide, is gradually increasing. Most studies on children who survive cancer show that the disease and its treatment have side effects and long-term late effects on the musculoskeletal system, physical function, gait and cognitive skills. Therefore, dual task gait performance, in which cognitive and motor tasks are performed simultaneously, may be affected in pediatric oncology patients. The aim of this study is to compare gait performance in single and dual task conditions in pediatric oncology patients with healthy controls.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04784026
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pediatric Cancer
Currently open trials in the same condition.
- NCT07506239 — Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma · NA · recruiting
- NCT07278778 — Cancer Care Companion · NA · recruiting
- NCT07473518 — Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy · recruiting
- NCT06939322 — LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) · NA · recruiting
- NCT07188311 — Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma · NA · recruiting
Other Afyonkarahisar Health Sciences University trials
Trials by the same sponsor.
- NCT07482501 — Repetitive Transcranial Magnetic Stimulation in Cardiac Autonomic Dysfunction · NA · recruiting
- NCT07445594 — Effect of Play Dough, Slime, and Plush Toys on Dental Anxiety and Pain in Children During Dental Treatment · NA · not yet recruiting
- NCT07421206 — DETERMINATION OF THE EFFECTS OF STAINLESS STEEL CROWNS CEMENTED WITH RESIN CEMENTS ON INTERLEUKIN-10, 12, 18 LEVELS IN G · NA · not yet recruiting
- NCT07340385 — Physiological and Biochemical Responses to Blood Flow Restriction Training · recruiting
- NCT07312812 — The Effect of Art-Based Mandala Coloring Activity on Postpartum Anxiety and Postpartum Depression · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04784026 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Afyonkarahisar Health Sciences University
- Last refreshed: 5 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04784026.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing